Day: December 10, 2024

Form 8.3 – [EQUIPMAKE HOLDINGS PLC – Opening Disclosure – 06 12 2024] – (CGAML)

Written by Customer Service on December 10, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree EQUIPMAKE HOLDINGS PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Edible Garden Drives Distribution of USDA Organic Herbs at Additional Key Food, City Supermarket and Lincoln Market Locations in NY Metropolitan Area

Written by Customer Service on December 10, 2024. Posted in Public Companies.

BELVIDERE, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, sustainable produce and products, today announced that it has expanded distribution of its USDA Organic herb product line to include additional Key Food, City Supermarket and Lincoln Market locations. “We are pleased to deepen our relationship with Key Food, City Supermarket, and Lincoln Market to make our USDA Organic herb line available in even more locations across the New York Metropolitan Area,” said Jim Kras, CEO of Edible Garden. “As ‘The Flavor Maker, Edible Garden®’, our mission is to deliver the freshest and most flavorful herbs to our retail partners. This expansion allows even more...

DatChat Awarded New U.S. Patent for its Blockchain-Based Communications Systems and Methods

Written by Customer Service on December 10, 2024. Posted in Public Companies.

New Brunswick, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) — DatChat, Inc (Nasdaq: DATS), a secure messaging and social media company, today announced that it has been granted a new US Patent (No. 12,166,889) supporting its Myseum platform, scheduled to launch in Q1 2025. Myseum is DatChat’s social media platform designed for storing and sharing digital media content securely and permanently. It allows users to create a digital legacy that can be easily shared both today and future generations. The new patent will expand DatChat’s IP and portfolio to 14, advancing the Company’s mission to creating a secure, multi-tiered social media ecosystem to users allowing them to securely share and store digital content, including messages, photos, videos, and documents, while maintaining privacy and security. About DatChat, Inc. DatChat, Inc. is a...

Form 8.3 – [LOUNGERS PLC – 09 12 2024] – (CGWL)

Written by Customer Service on December 10, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LOUNGERS PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Ollie’s Bargain Outlet Holdings, Inc. Reports Third Quarter Fiscal 2024 Financial Results

Written by Customer Service on December 10, 2024. Posted in Earnings Releases And Operating Results.

~ Net Sales increased 7.8% ~ ~ Earnings per Share increased 13.7% to $0.58 ~ ~ Opened Record 24 new stores this quarter ~ HARRISBURG, Pa., Dec. 10, 2024 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today reported financial results for the third quarter ended November 2, 2024. Third Quarter Summary:Total net sales increased 7.8% to $517.4 million. Comparable store sales decreased 0.5% from the prior year increase of 7.0%. The Company opened 24 new stores and closed three stores, including two permanent closures and one temporary closure related to Hurricane Helene, ending the quarter with 546 stores in 31 states, a year-over-year increase in store count of 8.1%. Operating income increased 14.0% to $44.5 million and operating margin increased 50 basis points to 8.6%. Net income increased...

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

Written by Customer Service on December 10, 2024. Posted in Earnings Releases And Operating Results.

Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA-1207 Fourth quarter pipeline advances include initiation of the Phase 1 trial for LAVA-1266, for hematologic malignancies, and a $5.0 million milestone payment from Johnson and Johnson Cash runway extended into 2027, based on a cash balance of $78.9 million, as of September 30, 2024UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, reported financial results for the third quarter ended September 30, 2024...

Stryker declares an $0.84 per share quarterly dividend

Written by Customer Service on December 10, 2024. Posted in Dividend Reports And Estimates.

Portage, Michigan, Dec. 10, 2024 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable January 31, 2025 to shareholders of record at the close of business on December 31, 2024, representing an increase of 5.0% versus the prior year and previous quarter. “We continue to deliver strong financial results, and consistent with our capital allocation priorities we are raising our dividend 5.0%,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside...

Man Group PLC : Form 8.3 – International Distribution Services plc

Written by Customer Service on December 10, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree International Distribution Services plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For...

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

Written by Customer Service on December 10, 2024. Posted in Public Companies.

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndromeACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug No cases of amyloid-related imaging abnormalities observed in this study population Based upon these findings, AC Immune plans to open the high-dose cohort in ABATE in individuals with Down syndromeLausanne, Switzerland, December 10, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim safety and tolerability data from the ABATE Phase 1b/2 trial of ACI-24.060 in individuals living with Down syndrome (DS). Targeting toxic forms of amyloid beta (Abeta), ACI-24.060 is an active immunotherapy...

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Written by Customer Service on December 10, 2024. Posted in Public Companies.

Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancerWith a median follow-up of 12 months, median progression-free survival (PFS) has not been reached 6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibitor treatment; data continue to mature Conference call today at 8:00 a.m. ETSAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast...

Day: December 10, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals